Expertise in
1
conditions

Dr. Amina Haggag

Family Medicine
Office
2441 W La Palma Ave Ste 140, 
Anaheim, CA 
Expertise in
1
conditions
Office
2441 W La Palma Ave Ste 140, 
Anaheim, CA 

Overview

Amina Haggag is a primary care provider, practicing in Family Medicine in Anaheim, California.

Dr. Haggag is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Maturity Onset Diabetes of the Young, Type 2 Diabetes (T2D), and Magnesium Deficiency.

She is actively involved in clinical research, co-authoring 5 peer reviewed articles and participating in 16 clinical trials.

Specialties

Family Medicine

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

HMSA
  • HMO
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
View 2 Less Insurance Carriers -

Locations

Office
2441 W La Palma Ave Ste 140, Anaheim, CA 92801

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Subcutaneous Doses of LY3493269 in Patients With Type 2 Diabetes Mellitus
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Subcutaneous Doses of LY3493269 in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug
Study Phase: Phase 1
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3457263 Alone and in Combination With GLP-1 RA in Patients With Type 2 Diabetes
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3457263 Alone and in Combination With GLP-1 RA in Patients With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: January 11, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drugs: LY3502970, Dulaglutide
Study Phase: Phase 2
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Drug
Study Drug: LY3502970
Study Phase: Phase 2
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Drug
Study Drug: LY3437943
Study Phase: Phase 2
Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Dapirolizumab Pegol (BIIB133) in Healthy Japanese and Caucasian Study Participants
Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Dapirolizumab Pegol (BIIB133) in Healthy Japanese and Caucasian Study Participants
Enrollment Status: Completed
Publish Date: April 18, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Open-Label, Parallel-Arm Study to Assess the Pharmacokinetic Comparability of 2 Fixed Subcutaneous Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous Dose in Healthy Volunteers
A Randomized, Open-Label, Parallel-Arm Study to Assess the Pharmacokinetic Comparability of 2 Fixed Subcutaneous Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous Dose in Healthy Volunteers
Enrollment Status: Completed
Publish Date: April 18, 2023
Intervention Type: Biological
Study Phase: Phase 1
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3540378 in Healthy Participants
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3540378 in Healthy Participants
Enrollment Status: Completed
Publish Date: June 21, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Patients With Type 2 Diabetes Mellitus
A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: January 20, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2, Multi-Center, Open-Label Study to Evaluate Long-term Safety and Efficacy of CXA-10 in Subjects With Pulmonary Arterial Hypertension on Stable Background Therapy: Extension to Study CXA-10-301
A Phase 2, Multi-Center, Open-Label Study to Evaluate Long-term Safety and Efficacy of CXA-10 in Subjects With Pulmonary Arterial Hypertension on Stable Background Therapy: Extension to Study CXA-10-301
Enrollment Status: Terminated
Publish Date: August 26, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

5 Total Publications

Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist.
Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist.
Journal: Diabetes, obesity & metabolism
Published: September 20, 2024
Similar Doctors
Expertise in
2
conditions
Dr. Susan Hutchinson
Family Medicine
Expertise in
2
conditions
Dr. Susan Hutchinson
Family Medicine

Office

33 Creek Rd Ste 340C, 
Irvine, CA 
 (56.3 miles away)
949-861-8717
Languages Spoken:
English
See accepted insurances

Susan Hutchinson is a primary care provider, practicing in Family Medicine in Irvine, California. Dr. Hutchinson is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Migraine and Headache.

Expertise in
96
conditions
Dr. Yuan Q. Liu
Family Medicine
Expertise in
96
conditions
Dr. Yuan Q. Liu
Family Medicine
701 S Atlantic Blvd Ste 100, 
Monterey Park, CA 
 (25.2 miles away)
626-300-9980
Languages Spoken:
English
See accepted insurances

Yuan Liu is a primary care provider, practicing in Family Medicine in Monterey Park, California. Dr. Liu is highly rated in 96 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Lung Adenocarcinoma, Arthritis, Liver Transplant, and Tissue Biopsy.

Expertise in
9
conditions
Dr. Joshua J. Solomon
Family Medicine
Expertise in
9
conditions
Dr. Joshua J. Solomon
Family Medicine

Playa Vista Medical Offices

5300 Mcconnell Ave, 
Los Angeles, CA 
 (17.9 miles away)
833-574-2273
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Joshua Solomon is a primary care provider, practicing in Family Medicine in Los Angeles, California. Dr. Solomon is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Rheumatoid Lung Disease, Interstitial Lung Disease, Acute Interstitial Pneumonia, Pulmonary Fibrosis, and Endoscopy. Dr. Solomon is currently accepting new patients.

Frequently Asked Questions about Dr. Amina Haggag

How do I make an appointment with Dr. Amina Haggag?

You can book an appointment with Dr. Amina Haggag by calling their office at 714-774-7777. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Amina Haggag a top-rated expert for Maturity Onset Diabetes of the Young?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Amina Haggag is classified as an Advanced expert for Maturity Onset Diabetes of the Young, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Amina Haggag specialize in?

While Dr. Amina Haggag is a Family Medicine, they have specific expertise in Maturity Onset Diabetes of the Young, Type 2 Diabetes (T2D), and Magnesium Deficiency. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Family Medicine.

Does Dr. Amina Haggag participate in research or clinical trials?

Yes. Dr. Amina Haggag has published 5 articles and abstracts on conditions like Maturity Onset Diabetes of the Young. You can view a list of Dr. Amina Haggag's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Amina Haggag accept my insurance?

Dr. Amina Haggag accepts most major insurance plans, including Anthem BCBS and Blue Shield of California. We recommend calling the office directly at 714-774-7777 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Haggag's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile